Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices 23735 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm 5152, MSC 

7844, Bethesda, MD 20892. (301) 435–1159. 

rubinsteinal@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, NCF 

Competitive Revisions. 

Date: June 5, 2009. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Fairmont Washington, DC, 2401 

M Street, NW., Washington, DC 20037. 

Contact Person: Lawrence Baizer, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4152, 

MSC 7850, Bethesda, MD 20892. (301) 435– 

1257. baizer@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, BPNS 

Competitive Revisions. 

Date: June 5, 2009. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Westin St. Francis Hotel, 335 

Powell Street, San Francisco, CA 94102. 

Contact Person: Geoffrey G. Schofield, 

PhD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4040–A, 

MSC 7850, Bethesda, MD 20892. (301) 435– 

1235. geoffreys@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Biomedical 

Informatics. 

Date: June 5, 2009. 

Time: 2 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Bill Bunnag, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3156, 

MSC 7770, Bethesda, MD 20892. (301) 435– 

1177. bunnagb@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, APDA: 

Review of Competing Revisions. 

Date: June 5, 2009. 

Time: 3 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Allerton Hotel Chicago, 701 

North Michigan Avenue, Chicago, IL 60611. 

Contact Person: Estina E. Thompson, PhD, 

MPH, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3178, 

MSC 7848, Bethesda, MD 20892. (301) 496– 

5749. thompsone@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Collaborative Applications in Adult 

Psychopathology and Disorders of Aging. 

Date: June 5, 2009. 

Time: 12 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Allerton Hotel Chicago, 701 

North Michigan Avenue, Chicago, IL 60611. 

Contact Person: Estina E. Thompson, PhD, 

MPH, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3178, 

MSC 7848, Bethesda, MD 20892. (301) 496– 

5749. thompsone@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, CMBG 

ARRA Competing Revisions. 

Date: June 5, 2009. 

Time: 12 p.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Toby Behar, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4136, 

MSC 7850, Bethesda, MD 20892. (301) 435– 

4433. behart@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Psychosocial Risk Prevention: ARRA 

Renewal Applications. 

Date: June 5, 2009. 

Time: 12 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Avenue Hotel Chicago, 160 Huron 

Street, Chicago, IL 60611. 

Contact Person: Anna L. Riley, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3114, 

MSC 7759, Bethesda, MD 20892. (301) 435– 

2889. rileyann@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: May 11, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–11580 Filed 5–19–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: The Development of 

Thalidomide Analogs for the Treatment 

of Cancer 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in US Patent Application 60/ 

792,098 entitled ‘‘Tetrahalogenated 

Compounds Useful as Inhibitors’’ [HHS 

Ref. E–080–2006/0–US–01], PCT 

Application PCT/US2007/008849 

entitled ‘‘Tetrahalogenated Compounds 

Useful as Inhibitors’’ [HHS Ref. E–080– 

2006/0–PCT–02], Australian Patent 

Application 2007238785 entitled ‘‘A 

New Series Of Thalidomide Analogs 

That Have Potent Anti-angiogenic 

Properties’’ [HHS Ref. E–080–2006/0– 

AU–03], Canadian Patent Application 

2,648,216 entitled ‘‘A New Series Of 

Thalidomide Analogs That Have Potent 

Anti-angiogenic Properties’’ [HHS Ref. 

E–080–2006/0–CA–04], European Patent 

Application 07755201.6 entitled ‘‘A 

New Series Of Thalidomide Analogs 

That Have Potent Anti-angiogenic 

Properties’’ [HHS Ref. E–080–2006/0– 

EP–05], US Patent Application 12/ 

287,597 entitled ‘‘A New Series Of 

Thalidomide Analogs That Have Potent 

Anti-angiogenic Properties’’ [HHS Ref. 

E–080–2006/0–US–06], and all 

continuing patents, patent applications, 

and foreign counterparts thereto, to 

CuriRx, Inc., which has offices in 

Andover, Massachusetts. The patent 

rights in these inventions have been 

assigned to and/or exclusively licensed 

to the Government of the United States 

of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to: 

The use of Gu998 (Compound 19e), Gu973 

(Compound 19f), Gu1029 (Compound 20d) or 

Gu992 (Compound 20g) as cancer 

therapeutics. 

23736 Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before July 

20, 2009 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: David A. Lambertson, 

Ph.D., Senior Licensing and Patenting 

Manager, Office of Technology Transfer, 

National Institutes of Health, 6011 

Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 435–4632; Facsimile: (301) 402– 

0220; e-mail: lambertsond@od.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

invention concerns the use of 

tetrahalogenated thalidomide 

derivatives for the treatment of cancer. 

Thalidomide has been shown to be a 

potent inhibitor of angiogenesis (the 

formation of new blood vessels). The 

popular belief is that angiogenesis 

enhances tumor formation by providing 

tumors with increased nutrients, 

allowing their sustained growth. 

However, thalidomide is a natural 

teratogen that can cause severe birth 

defects, and has a propensity towards 

causing neotropenia and deep venous 

thrombosis in recipients of the drug. 

This led researchers to seek out safer 

derivatives of thalidomide that retain an 

anti-cancer activity. The 

tetrahalogenated derivatives disclosed 

by this technology may represent both a 

safer alternative to thalidomide and 

potentially a more successful alternative 

to the angiogenesis inhibitors currently 

being clinically tested. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless 

within sixty (60) days from the date of 

this published notice, the NIH receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: May 12, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–11680 Filed 5–19–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: The Manufacture, Use, 

Distribution of and Sale of Fused 

Azepinone Cyclin Dependent Kinase 

Inhibitors as Therapeutics 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

Part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Patent No. 6,610,684 

entitled, ‘‘Fused Azepinone Cyclin 

Dependent Kinase Inhibitors’’ and all 

foreign counterparts [HHS Ref. No. 

E–025–1998/0] to ShanaRx 

Pharmaceuticals. The patent rights in 

this invention have been assigned to the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to the use 

of the Cyclin Dependent Kinase 

Inhibitors and their methods of use in 

the Licensed Patent Rights for the 

treatment of: (i) Disorders caused by 

damage, injury, infection in or abnormal 

function of the peripheral or central 

nervous system including pain, 

neuropathy, retinal degeneration, 

glaucoma, Alzheimer’s disease, 

Parkinson’s disease, ALS, depression, 

schizophrenia, and anxiety; (ii) 

disorders caused by damage, injury, 

infection in or abnormal function of 

cerebral vasculature and cardiac 

vasculature including cardiac failure 

and myocardial infections; (iii) cancer 

and neoplastic disorders; (iv) 

inflammatory and autoimmune diseases 

including Multiple Sclerosis; and (v) 

endocrine and neuroendocrine 

disorders including Diabetes Mellitus. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

August 18, 2009 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated co-exclusive license 

should be directed to: Whitney A. 

Hastings, M.S., Licensing and Patenting 

Manager, Office of Technology Transfer, 

National Institutes of Health, 6011 

Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804. Telephone: 

(301) 451–7337; Facsimile: (301) 402– 

0220; E-mail: hastingw@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

invention describes a class of cyclin 

dependent kinase (CDK) inhibitors that 

have anti-proliferative activity in human 

tumor cell lines. CDKs are important in 

the control of the cell cycle and 

alterations in CDK expression, function, 

or regulation are associated with 

diseases characterized by cellular 

proliferation. Increasing CDK activity 

has been reported in many cancers and 

observed in a wide variety of primary 

human tumors and human tumorderived cell lines, including lung, 

breast, brain, bone, skin, bladder, 

kidney, ovary, liver, colon, pancreas as 

well as in leukemia. The compounds of 

this invention have also been found to 

potently inhibit GSK3beta activity. 

Some of compounds of this invention 

have been shown to be more potent 

towards the GSK3beta target than 

towards CDKs. The GSK3beta enzyme, a 

proline-directed serine-threonine 

kinase, has been linked to a variety of 

cellular processes and several disparate 

areas of biology. Thus, this technology 

could provide therapeutic opportunities 

for a variety of indications, including 

Alzheimer’s, neurological disorders, and 

cardiac failure. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless 

within ninety (90) days from the date of 

this published notice, the NIH receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552.